patent.fyi
Applications  /  US 2026/0355115
United States Patent Application Publication

US 2026/0355115 A1

Published
Nov 12, 2026
Filed
Dec 18, 2023
Earliest date on the face
Dec 16, 2022
Classification
A61K 9/1647
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Phospholipid vesicle depot

What ifWhat if phospholipid vesicles hold the peptide in multiple internal aqueous compartments?
Claim language“polylactide-co-glycolide (PLGA)”

Phosphatidylcholine and cholesterol form membranes around aqueous chambers that contain the peptide. After injection, membrane reorganization and breakdown open diffusion paths from the chambers into tissue fluid.

1.2Lower payload per microsphere

What ifWhat if the peptide makes up 2 wt % of the dry microspheres?
Claim language“3 to 12 wt %”

Each milligram of dry microspheres contains 20 micrograms of peptide. The injection delivers the target peptide dose using 50 mg of dry microspheres per milligram of peptide, and the hydrated polymer matrix controls release.

1.2Higher payload in the core

What ifWhat if the peptide makes up 15 wt % of the dry microspheres and is concentrated in a core surrounded by a PLGA shell?
Claim language“3 to 12 wt %”

Coaxial droplet formation encloses a peptide-rich inner phase in a PLGA-rich outer phase. Solvent extraction hardens the outer phase into a shell that limits early peptide loss, and pores that form during hydrolysis permit release.

1.3Single polymer grade matrix

What ifWhat if the matrix contains a single ester-terminated PLGA grade with an intrinsic viscosity of 0.36 dL/g?
Claim language“a mixture of one type of low-viscosity PLGA”

Solvent extraction hardens emulsion droplets containing the single polymer grade into dense microspheres. After injection, water penetrates the matrix, and chain cleavage gradually creates connected pores through which the peptide diffuses.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Microsphere depots for perfused cell assays

GLP-1 receptor agonist microspheres made with one low-viscosity PLGA grade and two high-viscosity PLGA grades sit in an upstream chamber of a perfused pancreatic islet assay. A porous membrane retains the microspheres while allowing dissolved agonist to enter the medium flowing into the islet chamber. The assay records insulin secretion during scheduled glucose pulses and measures agonist concentration in the medium entering the islet chamber.

Component substitution

Polycaprolactone replaces one high-viscosity grade

Polycaprolactone replaces one of the two high-viscosity PLGA grades in a matrix containing low-viscosity PLGA and the remaining high-viscosity PLGA. The three polymers dissolve in dichloromethane, and an aqueous GLP-1 receptor agonist solution disperses in the polymer solution as fine droplets. The resulting emulsion disperses in an aqueous polyvinyl alcohol bath, and solvent extraction hardens the droplets into microspheres. The hydrated PLGA phase and the slower-eroding polycaprolactone phase govern water ingress and peptide release.

Parameter or scale variation

Bimodal microsphere diameter distribution

Two microsphere populations contain 6 wt% GLP-1 receptor agonist and the same blend of one low-viscosity PLGA grade and two high-viscosity PLGA grades. Wet sieving isolates diameter fractions of 20 to 35 µm and 60 to 85 µm, which are dried and combined at a 25:75 mass ratio. The smaller population supplies more surface area per unit mass, and the larger population provides longer diffusion paths from the particle interior.

Combination with existing systems

Dual-chamber syringe for depot reconstitution

A bypass syringe holds freeze-dried GLP-1 receptor agonist microspheres in its front chamber and an aqueous suspending vehicle in its rear chamber. The microspheres contain one low-viscosity PLGA grade and two high-viscosity PLGA grades, while the vehicle contains sodium carboxymethylcellulose and a nonionic surfactant. Plunger travel moves the separating stopper to the bypass channel and transfers the vehicle into the front chamber. Gentle inversion disperses the microspheres before the same syringe delivers the suspension.

Microsphere depots in a porous hydrogel

GLP-1 receptor agonist microspheres containing one low-viscosity PLGA grade and two high-viscosity PLGA grades are suspended in an aqueous sodium alginate solution. The suspension is cast in a shallow mold and contacted with calcium chloride solution to form a calcium alginate gel around the particles. The gel retains the microspheres, and released agonist diffuses through the hydrated gel into the surrounding fluid. Gel thickness sets the diffusion distance between the embedded microspheres and the surrounding fluid.

Automated or data-driven variant

Closed-loop droplet sizing during emulsification

A flow-focusing emulsifier forms droplets from a dispersed feed containing the GLP-1 receptor agonist and a blend of one low-viscosity PLGA grade and two high-viscosity PLGA grades. A downstream camera measures droplet diameters before solvent extraction, and a feedback controller adjusts the continuous-phase pump speed to hold the median droplet diameter at a calibrated setpoint. Calibration pairs the measured droplet diameter with the final dried microsphere diameter to account for shrinkage during hardening.

Specific version of a part

Intermediate viscosity polymer fraction

The three grades dissolve in a common organic phase before droplet formation and solvent extraction. The lower-molecular-weight chains in the blend reach water-soluble sizes sooner during hydrolysis, while the higher-molecular-weight fraction maintains the particle matrix longer.

Peptide salt in PLGA

An aqueous solution of a GLP-1 receptor agonist acetate salt forms the inner phase of a water-in-oil-in-water emulsion. The organic phase contains dissolved PLGA, which hardens around the inner droplets as the solvent transfers into the outer aqueous phase.

Eight percent dry payload

Dried microspheres contain 8 mg of GLP-1 receptor agonist per 100 mg of total particle mass. A liquid chromatography assay quantifies the peptide after extraction from a weighed sample of the dried microspheres.

Three PLGA viscosity grades

The polymer blend contains grades with intrinsic viscosities of 0.20, 0.38, and 0.50 dL/g at a dry polymer mass ratio of 20 to 40 to 40. The grades dissolve together in the organic phase before emulsification and solidify together during solvent extraction.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2010/0137212 A1
Published
Jun 3, 2010
Filed
Apr 24, 2008
Class
A61K 38/22
Document BUS 2012/0294855 A1
Published
Nov 22, 2012
Filed
Oct 28, 2010
Class
A61K 38/26
Claim 1
Document A
Document B
1.1a GLP-1 receptor agonist or a pharmaceutically acceptable salt thereof and polylactide-co-glycolide (PLGA),
In other embodiments, the present invention provides pharmaceutical compositions including a pharmaceutically acceptable excipient along with a therapeutically effective amount of a GLP-1 receptor agonist or an incretin mimetic.
A · US 2010/0137212 A1 · ¶ 39
The disclosure also provides pharmaceutical compositions comprising the GLP-1 receptor agonist compounds described herein and a pharmaceutically acceptable carrier.
B · US 2012/0294855 A1 · ¶ 29
1.2wherein the GLP-1 receptor agonist or the pharmaceutically acceptable salt thereof is included in an amount of 3 to 12 wt % of the total wt %, and
1.3wherein the PLGA is a mixture of one type of low-viscosity PLGA with an intrinsic viscosity of 0.14 to 0.24 dL/g and two or more types of high-viscosity PLGA with an intrinsic viscosity of 0.32 to 0.60 dL/g.

An empty cell means only that no passage was reproduced there.

Statements in these documents
This invention relates to the use of GLP-1 receptor agonists to treat short bowel syndrome and spastic or hyperactive esophageal motor disorders.
A · US 2010/0137212 A1 · ¶ 1
Thus, there is a need in the art for alternative or improved methods and compositions to treat short bowel syndrome.
A · US 2010/0137212 A1 · ¶ 6
There exists a need in the art to identify therapeutic agents that can be used to enhance the quality of sleep and treat sleep apnea without causing patient discomfort.
B · US 2012/0294855 A1 · ¶ 5
Methods for treating obstructive sleep apnea include methods for reducing the severity of obstructive sleep apnea.
B · US 2012/0294855 A1 · ¶ 6
Cite aspatent.fyi, US 2026/0355115 A1, claim 1, first published 2026-11-19T08:28:42-05:00, https://patent.fyi/US20260355115/, SHA-256 efea3eba6a326fbf040fac5fb42c7b7f68e3b4269774f20d144fd9ab7bae1d07
First published
Permanent addresshttps://patent.fyi/US20260355115/
Content fingerprint (SHA-256)efea3eba6a326fbf040fac5fb42c7b7f68e3b4269774f20d144fd9ab7bae1d07
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi